Product news

PC945 in phase 1 study

Pulmocide today announces the successful dosing PC945 in a phase 1 study. PC945 is a novel antifungal agent which is delivered by inhaled administration for the treatment of Aspergillus Fumigatus […]

21 November 2017

Read more

PC786 in phase 1 study

Pulmocide  a clinical-stage company today announces the successful dosing of PC786 in a phase 1 study. PC786 is a potent inhibitor of RSV L polymerase which is delivered by inhaled administration for the treatment of RSV A and B […]

19 July 2017

Read more